Gilead Sciences (NASDAQ:GILD) Upgraded by Scotiabank to Strong-Buy Rating

Gilead Sciences (NASDAQ:GILD) was upgraded by stock analysts at Scotiabank to a “strong-buy” rating in a report released on Wednesday,Zacks.com reports.

A number of other research analysts also recently commented on the stock. Weiss Ratings reissued a “buy (b)” rating on shares of Gilead Sciences in a research report on Wednesday, October 8th. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Royal Bank Of Canada lifted their target price on Gilead Sciences from $100.00 to $105.00 and gave the stock a “sector perform” rating in a research note on Friday, October 31st. UBS Group increased their price target on Gilead Sciences from $108.00 to $112.00 and gave the company a “neutral” rating in a research note on Friday, August 8th. Finally, Daiwa Capital Markets upped their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average price target of $129.13.

Gilead Sciences Trading Up 1.5%

Shares of NASDAQ:GILD opened at $125.20 on Wednesday. The company’s 50-day moving average price is $117.24 and its two-hundred day moving average price is $112.64. Gilead Sciences has a one year low of $86.08 and a one year high of $127.68. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The stock has a market capitalization of $155.33 billion, a PE ratio of 24.94, a price-to-earnings-growth ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm had revenue of $7.77 billion during the quarter, compared to analysts’ expectations of $7.42 billion. During the same period in the prior year, the firm posted $2.02 earnings per share. The business’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. On average, equities analysts forecast that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Activity at Gilead Sciences

In other news, EVP Deborah H. Telman sold 53,646 shares of the business’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $122.85, for a total transaction of $6,590,411.10. Following the sale, the executive vice president directly owned 43,676 shares in the company, valued at approximately $5,365,596.60. The trade was a 55.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $118.08, for a total transaction of $295,200.00. Following the sale, the chief financial officer owned 157,055 shares in the company, valued at approximately $18,545,054.40. This represents a 1.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 94,646 shares of company stock worth $11,311,286. Corporate insiders own 0.27% of the company’s stock.

Institutional Trading of Gilead Sciences

Several institutional investors have recently modified their holdings of the business. Trivium Point Advisory LLC increased its holdings in Gilead Sciences by 1.1% in the 3rd quarter. Trivium Point Advisory LLC now owns 7,325 shares of the biopharmaceutical company’s stock valued at $813,000 after acquiring an additional 83 shares during the last quarter. Rothschild Investment LLC raised its holdings in shares of Gilead Sciences by 1.9% during the 2nd quarter. Rothschild Investment LLC now owns 4,539 shares of the biopharmaceutical company’s stock worth $503,000 after acquiring an additional 84 shares in the last quarter. Hemington Wealth Management boosted its position in shares of Gilead Sciences by 9.3% during the 3rd quarter. Hemington Wealth Management now owns 998 shares of the biopharmaceutical company’s stock valued at $110,000 after acquiring an additional 85 shares during the last quarter. Ignite Planners LLC grew its holdings in shares of Gilead Sciences by 1.1% in the third quarter. Ignite Planners LLC now owns 7,932 shares of the biopharmaceutical company’s stock valued at $880,000 after purchasing an additional 86 shares in the last quarter. Finally, Archer Investment Corp increased its position in Gilead Sciences by 1.2% in the second quarter. Archer Investment Corp now owns 7,277 shares of the biopharmaceutical company’s stock worth $807,000 after purchasing an additional 87 shares during the last quarter. Institutional investors own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.